Introduction
While cancer development in humans is a multi-step process often requiring years for the emergence of a malignant invasive tumor from premalignant lesions, it is not known if all premalignant lesions have an equal probability of progression or if a subset with higher risk for malignant potential exists. To test whether premalignant lesions have distinguishable stable gene expression profiles that define their risk for malignant progression, we have utilized a mouse model of chemically induced skin carcinogenesis where the multiple stages of cancer development are readily accessible and have been well characterized at both the tissue and molecular levels. Studies from multiple laboratories have shown that genetic changes occurring in this tumor model are relevant to pathways altered in human squamous cell carcinoma (SCC) and other cancers of lining epithelia (Yuspa, 1998) . In this model the mouse epidermis is treated with the carcinogen dimethyl benz[a]-anthracene (DMBA) followed by 20 weekly applications of a tumor promoter, such as 12-Otetradecanoylphorbol-13-acetate (TPA). Benign papillomas with initiating mutations in the c-Ha ras gene arise within 10-15 weeks, and a small percentage progress to locally invasive SCC. However, studies over the last decade have identified two subclasses of benign lesions with differing rate of premalignant progression and characterized several biomarkers that distinguish them at early stages (Hennings et al., 1985; Glick et al., 1993; Tennenbaum et al., 1993; Darwiche et al., 1996) . Lowrisk papillomas are terminally benign and do not progress to SCC, while a smaller fraction of benign tumors, termed high-risk papillomas, progress to SCC with high frequency. Differing tumor promotion protocols enrich for the low-or high-risk papilloma subtypes, and thus they can be readily and predictably isolated for further analysis (Hennings et al., 1985) . To test the hypothesis that high-risk papillomas represent the precursor lesions to SCC at the molecular level, we have used oligo microarrays to compare the gene expression profile of early stages of benign low-and high-risk papillomas in relationship to normal skin, chronic TPA promoted normal skin and SCC.
Results

Identification of differentially expressed genes in multistage skin carcinogenesis
Cutaneous squamous tumors were generated and analysed by microarray analysis as described in Materials and methods, and in Supplementary methods. To identify differentially expressed genes, expression ratios from filtered arrays were compared using ANOVA and genes selected with a Po0.001 between at least one group, or Significance Analysis for Microarrays (SAM) with a shrinkage of 4.5 and a false discovery rate of 0.0023. Both analyses identified 514 genes (Supplementary Table I ), with concordance of 87% between these two gene sets. Confirming the cross platform reproducibility of the mouse multistage skin model, this gene set contains highly induced and downregulated genes similar to another cDNA microarray study comparing pooled papillomas, SCC-and TPA-treated normal skin (Hummerich et al., 2006) , such as S100a9, S100a8, S100a11, small proline-rich proteins Sprr2f, Sprr2k, Slpi, the ras family member Arhh, Fabp5 and several members of the glutathione S-transferase family (Supplementary online dataset). Additional highly induced genes across all tumors identified in our dataset include markers of inflammation such as interleukin-1b (IL-1b), Ear5, pregnancy-specific glycoprotein 28 (Psg28) and the cysteine protease inhibitor stefin A1. Among the most highly downregulated genes across all tumors are mesenchymal proteins actin a1, g2, myosin1A and the cartilage associated homeobox gene Sox5.
We used semi-quantitative reverse transcriptase (RT)-PCR ( Figure 1 ) and quantitative RT-PCR (Supplementary Table II ) to validate the expression patterns for seven genes that were overexpressed in tumors (IL-1b, S100a8, S100a9, 2610528A11Rik, Stfa1, Birc5, Arg1); eight genes downregulated in tumors (2510006C20Rik, 1700013N18Rik, ChChd5, Dctn1, Rtn4, Nibrin, Mapk8ip3, Rbm12); and von Hippel-Lindau syndrome homologue a gene that distinguishes low-and high-risk tumors (Table 1) . The trend was similar, but expected variability in the ratios between the two methods was observed due to calculated average values obtained from different numbers of tissues and/or method sensitivity. Taken together these results as well as concordance of expression patterns in this dataset with published expression and array studies (Hummerich et al., 2006) show that the expression patterns observed with the oligo microarrays reflect valid differences in gene expression between groups of tumors.
High-risk papillomas cluster with squamous cell carcinomas We used multidimensional scaling (MDS) to represent in a three-dimensional space the relationship between each tumor based on the expression pattern. This analysis showed close similarity between the high-risk papillomas and SCC with the low-risk papillomas clustering in a tight group distinct from these tumors and normal skin (Figure 2a) . Similarly, unsupervised hierarchical clustering using a Pearson correlation of the individual tumor arrays generated a dendrogram that linked low-risk tumors to the normal skin samples, while the high-risk papillomas to that of the SCC (Figure 2b) . Three of the malignant tumors clustered with the lowrisk papillomas while one low-risk papilloma, 1B-50B, clustered with the SCC, even though histological examination of 1B-50B did not reveal invasion through the basement membrane (data not shown). In both analyses, one tumor generated using a high-risk promotion protocol, 1B-29B, clustered with the low-risk papillomas (Figure 2a and b, arrow) . To determine if this gene expression clustering correlated with previously identified markers of progression, the tumors were characterized for expression of keratins (K) 1, 10, 13 and 8 (Larcher et al., 1992; Tennenbaum et al., 1993) . As expected 10/10 low-risk papillomas expressed K1 and K10 throughout while K13 was absent or expressed in small foci (Figure 3 ). In contrast, 9/10 high-risk papillomas expressed K13 abundantly and exhibited varying degrees of K1 loss. In concordance with its expression profile, tumor 1B-29B generated with a highrisk promotion protocol had a keratin profile similar to low-risk papillomas (Figure 3) . None of the benign tumors were K8-positive while all of the SCC expressed this marker, suggesting that expression profiling can identify premalignant lesions before full acquisition of a malignant phenotype.
A molecular signature of low-risk papillomas linked to downregulated innate and adaptive immunity To identify genes that distinguish benign lesions with differing risk for malignant progression, we used the Expression profiling high-risk benign skin lesions N Darwiche et al (Tibshirani et al., 2002) tool present on the mAdB analysis program to identify genes that were significantly different between these two groups. For this analysis tumor 1B-29B was grouped with the low-risk papillomas. At the minimum misclassification error of 0.048, 87 genes were identified that classified the tumors into two groups. Of these genes, 54/87 (62%) had a similar expression pattern in both high-risk papillomas and SCC ( Figure 4 , Table 1 ). The most highly induced genes in high-risk papillomas were b-globin, three small nuclear RNAs, U4, U3A and 7S and several RIKEN sequences. In addition, the adhesion molecule intercellular adhesion molecule 1, the Ets-related transcription factor Erf1 and the tumor suppressor VHL were elevated in high-risk papillomas relative to low-risk papillomas. Surprisingly, genes directly involved in cell proliferation that were different between these two classes such as the mitotic regulator NIMA 4, uridine cytidine kinase 2, and ornithine decarboxylase antizyme Oaz1 were reduced in the high-risk papillomas. Reduced expression of signal transducers such as the guanine nucleotide binding protein a o, and cAMP-dependent protein kinase b-catalytic subunit also distinguished high-risk papillomas from low-risk tumors.
Twenty-eight percent (24/84) of the genes whose expression ratio was distinct between low and high-risk papillomas were associated with the immune response, and most were T-cell ab receptor (TCR) genes or genes encoding immunoglobulins that were downregulated in the high-risk papillomas. While gd TCR genes, characteristic of the most prominent epidermal T-cell class, were not present on the PAM list that segregated benign papillomas, within the entire 514 differentially expressed gene list there was a threefold reduction in expression of TCRd (T-cell receptor d-chain mRNA) from low-risk papillomas to high-risk papilloma and SCC. Other genes associated with inflammation and inflammatory pathways such as Traf2, and PMSD2 (TRAP2) involved in the TNF receptor signaling pathway, the pro-inflammatory chemokine CX3CL1 (fractalkine) and Hamp1 (Peyssonnaux et al., 2006) were expressed at lower levels or were downregulated in the high-risk papillomas and SCC compared to the low-risk papillomas. Additionally, genes such as Laf4, a B-cell transcription factor (Ma and Staudt, 1996) and amphoterin (HMG-1B), a chromatin protein with proinflammatory properties (Dumitriu et al., 2005) , and Lglas2 (galectin2), a b-galactosidasebinding protein that mediates lymphotoxin secretion (Ozaki et al., 2004) , were significantly downregulated in both the high-risk papillomas and SCC. The alternatively spliced form of IL15, a cytoplasmic isoform of the cytokine that impairs g-IFN production and T-and NK-cell responses (Nishimura et al., 1998 (Nishimura et al., , 2000 , was also highly upregulated in the high-risk papillomas and SCC. These data suggest that one early difference between low-risk and high-risk benign papillomas is the degree of anti-tumor immune response. To test this, both types of papillomas were assayed for the level of infiltrating lymphocytes using immunohistochemistry for the T-cell marker CD3e. Figure 5 shows that PAM analysis was performed on the expression ratios of low-risk and low-risk papillomas, and the resulting gene list obtained at a d of 2.8 and minimum misclassification error of 0.048. The resulting gene list was used to filter all tissue types and the expression ratios within each tissue class were averaged, and normalized to the ratio of normal mouse skin samples. cAMP, cyclic adenosine monophosphate; NIMA, never in mitosis gene a; PAM, prediction analysis for microarray; SCC, squamous cell carcinoma; TPA, 12-O-tetradecanoylphorbol-13-acetate.
Expression profiling high-risk benign skin lesions N Darwiche et al low-risk papillomas (6/6) have focal areas with high CD3e þ infiltration in the tumor epithelia and abundant CD3e þ cells in the tumor stroma, while within the highrisk papillomas tumor cell compartment and tumor stroma there are few CD3e þ cells in the high-risk tumor or tumor stroma. Thus, these results validate the microarray data showing reduced levels of TCR expression in the high-risk papillomas. Taken together these results suggest that although tumor development is associated with elevated expression of proinflammatory genes, high-risk benign lesions and SCC are associated with reduced T-cell-associated anti-tumor adaptive immunity.
A distinct profile for chronic tumor promotion linked to high-risk papillomas To rule out that the difference in gene expression profiles between low-and high-risk papillomas and SCC was due to persistent application of a tumor promoter to the low-risk papillomas, we examined expression of the 514 differentially expressed genes obtained from the initial analysis in skin treated chronically with TPA for 5 weeks. Similar to published studies of short-term TPA treatment (Schlingemann et al., 2003; Hummerich et al., 2006) , a number of genes were induced or downregulated in both TPA-treated skin and all tumors such as S100A8, several Sprr2 family members, PSG28, Esd, dynactin (dctn1) and myosin 1a Myo1A (Supplementary Table I ). Many genes were distinctly regulated between tumor-promoted normal skin and all tumors including arginase and Stefin A1, which were induced 3-20-fold in tumors but were either unaffected or downregulated in chronically tumor-promoted skin. MDS analysis of arrays from all tissues showed that the overall gene expression pattern of chronically phorbol ester-promoted skin was distinct from both normal skin and from all tumors (data not shown). These results demonstrate Lines represent clusters of genes whose expression pattern is similar between low-risk papillomas and squamous cell carcinoma (SCC) and distinct from other tissues. Normal skin (n ¼ 6), low-risk papillomas (n ¼ 10), high-risk papillomas (n ¼ 10) and SCC (n ¼ 6). In both methods, high-risk papillomas and SCC arrays show a high degree of similarity except for tumor 1B-29B, a high-risk tumor that clusters with the low-risk papilloma group (arrow). For both the multidimensional scaling (MDS) and hierarchical clustering, tissues are coded as yellow, normal skin; red, lowrisk papilloma; blue, low-risk papilloma; green SCC.
Expression profiling high-risk benign skin lesions N Darwiche et al that the difference in gene expression between the lowrisk and high-risk papillomas is not due to a difference in TPA treatment. Surprisingly, as shown in Table 1 , 64% (51/79) of the genes that distinguish low-and high-risk papillomas/SCC follow the high-risk/SCC pattern in chronic TPA-treated normal skin, while only 9/79 genes were similar between low-risk papillomas and chronic TPA treatment. Thus, chronic TPA promotion of normal skin causes changes in gene expression distinct from the majority of chronically promoted benign tumors, but produces an expression signature similar to high-risk papillomas and SCC.
Generation of a risk predictor for benign lesions
To test the robustness of the benign tumor classifier we utilized a different set of class prediction tools in the BRBArray Tools software program (NCI) to compare low and high-risk papillomas, and then used this classifier to predict the risk of independent coded unknown tumors generated using the two-stage carcinogenesis protocol. The sensitivity and specificity (Supplementary methods) of the classifiers was between 0.857 and 1 depending on the prediction method. Three low-risk tumors and three high-risk tumors were designated as test unknowns and the remainder used as a training set for class prediction. Genes were included at a univariate parametric significance level of Po0.0001. Except for one tumor that was misclassified by the support vector machines algorithm, all six classifiers were in agreement and correctly classified the test tumors based on keratin profiling, promotion protocols and previous hierarchical clustering. This list of 125 genes contained close to 50% of the genes present on the previously generated PAM gene list (Supplementary Table III) , and included many of the immune function genes such as Lgals2, Hamp1, IgK, Laf4, Traf2, and TCRb as well as CD2. We then used this Po0.0001 predictor gene set to classify eight coded not previously classified tumor samples with two previously classified as either low-or high-risk. Hierarchical clustering of these unknown tumors placed three high-risk papillomas (as determined by tumor induction protocol) in one cluster with a previously identified high-risk papilloma (1B-50C) and an unknown that was determined histologically to be a SCC, and four unclassified low-risk papillomas with a previously classified low-risk papilloma (2-53-D) ( Figure 6 ). To correlate the molecular risk prediction with known biomarkers, we stained the tumors with different keratin antibodies. There was a strong relationship between the keratin immunostaining pattern and the predicted risk group based on the array clustering. These results show that this methodology can predict the risk potential of a benign papilloma with high accuracy.
Discussion
Microarray technology has been used to identify gene expression patterns associated with different stages of cancer, different cancer types and to generate predictors of therapeutic response (Glinsky et al., 2004; Lossos et al., 2004; Nambiar et al., 2004; Juric et al., 2005) . In the mouse skin carcinogenesis model microarrays have identified genes whose expression is associated with tumor promotion, with benign and malignant stages of tumor progression or with malignant progression and metastasis (Dong et al., 1997; Serewko et al., 2002; Dooley et al., 2003; Hummerich et al., 2006; Ridd et al., 2006) . Similar to many human epithelial cancers that arise from premalignant lesions such as superficial bladder dysplasia, oral leukoplakia or actinic keratoses with unknown risk for malignant conversion (Callen et al., 1997) , benign tumors generated in the mouse multistage skin carcinogenesis model differ in malignant potential and express unique phenotypic markers (Hennings et al., 1985; Glick et al., 1993; Tennenbaum et al., 1993; Darwiche et al., 1996) . In this report, we have used microarray analysis to test the hypothesis that high-risk papillomas share a gene expression pattern with and thereby represent the likely precursor lesion to SCC. While there were patterns of gene expression that were common to all tumors, two clustering methods using a database of 514 differentially expressed genes closely linked the gene expression profile of high-risk papillomas and SCC. These results demonstrate that within a large cohort of histologically and biologically benign tumors subpopulations of tumors exist with distinct gene expression patterns that relate to their malignant potential. In addition, this expression clustering Ethanol-fixed tissue sections from all low-and high-risk papillomas and SCC were immunostained for keratins 1, 13 and 8 as described in Materials and methods. The pattern shown for the low-risk and high-risk papillomas is representative of 10/10 high-risk papillomas and 9/10 high-risk tumors. The tumor 1B-29B was generated with the highrisk tumor promotion protocol, but clustered with the low-risk group based on expression analysis and histochemical phenotyping.
Expression profiling high-risk benign skin lesions N Darwiche et al Figure 4 An expression signature predicts risk group of unknown squamous tumors. Genes that distinguish low-and high-risk papillomas show similar pattern of expression in normal skin and squamous cell carcinoma (SCC), respectively. Arrays from normal skin, benign tumors and SCC were filtered using an 87 gene list generated using prediction analysis for microarray (PAM) comparison between low-risk and highrisk papillomas with a misclassification rate of 0.048. Filtered expression ratios were averaged within each group to generate heat map.
Expression profiling high-risk benign skin lesions N Darwiche et al correctly distinguished a tumor generated by the lowrisk promotion protocol that had a phenotypic profile characteristic of the low-risk papillomas. Of the 514 differentially regulated genes, we identified a set of 87 that represented significant classifiers for either the lowor high-risk papilloma state. When these arrays were divided into training and unknown sets this classifier list correctly predicted the risk group of the six 'unknown' tumors. Similarly, using a second classification method we correctly grouped 9/10 unknown tumors into low or high-risk groups. While a larger unknown tumor set is needed to test the predictive nature in this model, and we have not determined the minimum classifier needed, these results suggest that this methodology can be used to distinguish benign lesions at differing risks for progression. A large fraction of the genes whose expression changes during tumor progression is associated with inflammation and adaptive immunity. Based on human studies and some experimental models that show a link between inflammation and tumor development (Coussens et al., 1999; Balkwill and Mantovani, 2001; Coussens and Werb, 2002; de Visser et al., 2005) , it is widely believed that chronic inflammation acts to promote cancer development. Indeed in both this report and a previous microarray study (Hummerich et al., 2006) many proinflammatory genes are upregulated during squamous tumor development with the highest expression in benign low-risk papillomas. However, in contrast to a model of HPV-E6/E7 driven cutaneous tumor formation where inflammation and antibody deposition underlie the pathogenesis of the disease (Coussens et al., 1999; de Visser et al., 2005) , our data show that high-risk papillomas and SCC are distinguished by reduced expression of genes associated with T cells, B cells and adaptive immunity. These results support the concept that immunosurveillance mechanisms exist that function to recognize and eliminate developing tumor cells, and that defects in immunosurveillance are associated with tumor progression (Dighe et al., 1994; Kaplan et al., 1998; Smyth et al., 2000; Girardi et al., 2001 Girardi et al., , 2003 . Our results suggest that premalignant tumors with high expression of inflammation-associated genes and T-and B-cell-specific products remain terminally benign, and that the rapid appearance of high-risk lesions after onset of promotion may be due to reduced anti-tumor immunity acting to slow outgrowth of initiated keratinocytes.
It was expected, but not observed, that low-risk papillomas would have a largely overlapping gene expression profile with chronically TPA-treated normal skin due to the repeated application of TPA to these tumors. While there was overlap between chronic TPA and all tumors, there were very few genes whose expression pattern was uniquely common to low-risk papillomas and TPA-treated skin. Instead, chronic TPA promotion produced an expression pattern similar to that of high-risk papillomas and SCC within the context of genes that distinguished these tumors from low-risk papillomas. The expression pattern of genes that distinguish tumors that ultimately progress to malignancy can be detected in as little as 5 weeks of promotion of normal uninitiated skin. Thus, even 8 weeks after last TPA treatment high-risk papillomas retain an expression pattern similar to chronically promoted skin, suggesting that these represent autonomous or self-promoting lesions. That the high-risk expression signature is evident after 5 weeks of promotion in normal skin suggests that the keratinocyte progenitor of the high-risk papilloma and the keratinocytes that persist in the epidermis after long-term promotion are closely linked. It remains to be determined, however, if the precursor to high-risk papillomas originates in follicular stem cells, while low-risk papillomas originate from interfollicular keratinocytes. Recent studies showing that SCC arise from hair follicle stem cells, while the majority of benign papillomas arise from interfollicular keratinocytes support this concept (Morris et al., 1997 (Morris et al., , 2000 Brown et al., 1998; PerezLosada and Balmain, 2003) .
Validation of these gene lists as predictive markers for human cancers remains to be determined. Using the online Oncomine human cancer microarray database ) which allows crossplatform comparison of cancer array data from multiple published studies, we find that 22 of the PAM list genes were significantly changed in several human cancers relative to normal. In all lung cancers arrays, 9 of the 13 total identified changed genes followed a similar pattern as the low-risk papillomas in this study. CXC3CL1 (fractalkine) was decreased in multiple lung cancer types as well as liver, breast and prostate cancer relative to normal suggesting that decreased expression of this chemokine may be of predictive value in some human cancers. Other genes in the high-risk signature that are expressed in a similar pattern in human cancers include Laf4, decreased in lung SCC and adenocarcinoma, RNF3 increased in prostate carcinoma, intercellular adhesion molecule 1 (ICAM1) increased in HNSCC, and VHL increased in lung adenocarcinoma and metastatic prostate carcinoma. While these specific genes may be only directly relevant to the two-stage skin carcinogenesis model, these results provide strong evidence for heterogeneity in global gene expression patterns of premalignant lesions that is linked to phenotypic heterogeneity and risk for malignant conversion. This suggests that expression analysis of human premalignant lesions could provide diagnostic biomarkers for cancer risk as well as novel therapeutic targets for high-risk lesions.
Materials and methods
Tumor generation and characterization
Tumors were induced in 7-8-week-old outbred female SENCAR mice using a one time treatment with DMBA (5 mg) and TPA (2 mg) once per week for variable times as described (Hennings et al., 1985) . Low-risk papillomas were generated by continuous TPA promotion for 14-15 weeks and were harvested 3 days after the last TPA treatment. High-risk papillomas were induced by 7 weeks of TPA promotion and harvested at 14-15 weeks. SCCs generated in either tumor induction protocol were harvested as they appeared. Normal skin was isolated from 7-8-week-old SENCAR mice in the telogen stage of hair cycle. Hyperplastic non-initiated skin was generated by 5 weeks of TPA treatment (2 mg) once per week and was harvested 3 days after the last TPA treatment. Histology of tumors and staging were characterized by hematoxylin and eosin staining and through anti-keratin immunostaining.
Microarray design and analysis and validation
See Supplementary Information for detailed description of microarray methodology, analysis and validation by semiquantitative and quantitative reverse transcription-PCR. All original microarray data has been deposited to the GEO website http://www.ncbi.nlm.nih.gov/geo/, accession number GSE5576.
Immunohistochemistry
Keratins were detected in 70% ethanol-fixed tissue sections using monospecific rabbit antibodies to keratins K1, K10, K13 (Covance Research Products, Berkeley, CA, USA) or a monoclonal anti-K8 (Developmental Studies Hybridoma Bank, University of Iowa, IA, USA), and T cells were detected in 70% ethanol fixed tissue sections using an anti-CD3e antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Bound antibodies were detected using appropriate biotinylated secondary antibodies and the Vectastain Elite Kit (Vector Laboratories, Burlingame, CA, USA) as described previously A classifier that predicts risk for unknown benign papillomas. Arrays performed on known and unknown skin tumors were filtered using a 125 gene list obtained using a covariate classifier algorithm in BRBArray tools (Supplementary methods) and then clustered hierarchically using centered correlation and average linkage. The associated table for each tumor on the dendrogram shows the tumor promotion protocol, histology, keratin staining profile and risk group as determined by expression of genes within the classifier, and phenotypic analysis (histology and keratin immunostaining). Unknowns 1 and 2 were previously analysed as low-and high-risk papillomas 2-53-D and 1B-50A, respectively, which were used as internal controls for clustering.
Expression profiling high-risk benign skin lesions N Darwiche et al 12-O-tetradecanoylphorbol-13-acetate; TCR, T cell receptor; TPR, tetratrico peptide repeat; ETS, E26 transformation specific.
